Does Local Administration of Liposomal Bupivacaine Reduce Pain and Narcotic Consumption in Adult Spinal deformity Surgery?

Andrew S. Chung, DO¹, Dennis Crandall, MD¹,², Jan Revella, RN², Biodun Adeniyi², Yu Hui H. Chang, PhD³, and Michael S. Chang, MD¹,²

Abstract

Study Design: Retrospective cohort study.
Objective: To determine if local administration of liposomal bupivacaine (LB) reduces postoperative pain scores and narcotic use in spinal deformity patients.
Methods: Adult patients undergoing elective spinal fusion (7 or more levels) for scoliosis or kyphosis were selected for inclusion. Patients received either periincisional injections of combined liposomal and standard bupivacaine (n = 90, group L) or standard bupivacaine only (n = 69, group C). Perioperative pain scores (VAS [visual analogue scale]), opioid use, length of stay, functional outcome (ODI [Oswestry Disability Index]), and perioperative complications were recorded. No external funding was received for this study.
Results: A total of 159 patients met inclusion criteria (mean age was 54.2 years of age). No significant baseline demographic differences were noted between the 2 groups. Group L experienced slight improvements in pain control on postoperative day (POD) 1 (P = .02). No difference in pain scores were otherwise noted. Group L transitioned off of intravenous (IV) narcotics faster with 52.6% less IV use by POD3 (P = .03). No differences in total narcotic consumption, perioperative complications, lengths of stay, and functional outcome scores were otherwise noted between the 2 cohorts.
Conclusions: The use of LB in adult spinal deformity surgery does not appear to provide clinically important improvements in postoperative pain at the manufacturer’s recommended dosage. Furthermore, while patients receiving LB may transition more quickly off of IV narcotics, this does not appear to translate into an overall decrease in narcotic consumption, hasten return of bowel function, or decrease hospital lengths of stay. Future prospective randomized control trials are warranted. The use of varying dosages of LB may also help further clarify the true efficacy of LB in the setting of spinal deformity surgery.

Keywords
spinal deformity, opioids, liposomal bupivacaine, pain, exarel, multimodal, adult

Introduction

Adult spinal deformity (ASD) affects up to 60% of the older population. While only 6% of these patients are symptomatic, pain, which may be severe, is the most common associated symptom.¹,² Consequently, ASD has been associated with poor health-related quality of life measures¹,³ and may even be more physiologically debilitating than other chronic disease states such as diabetes, congestive heart failure, and chronic obstructive pulmonary disease.⁴ Fortunately, surgical deformity correction has been shown to substantially improve outcomes in these...
patients.\textsuperscript{2,5} However, as these surgeries can be associated with significant morbidity, consequent postoperative pain may be quite severe.

Inadequate postoperative pain management has been shown to increase the risk of perioperative complications such as thromboembolic events and pulmonary complications in many surgical settings.\textsuperscript{6-8} Furthermore, poor pain control in the first 48 hours following spinal surgery has been correlated with only a 50\% chance of achieving long-term satisfactory pain relief.\textsuperscript{7} On the contrary, adequate pain management following spinal surgery has been associated with quicker mobilization, decreased narcotic consumption, and shorter hospital lengths of stay.\textsuperscript{9,10} However, the most optimal pain regimen following spine surgery remains to be determined.

Surgical site infiltration with an amide anesthetic has long been utilized as an adjunctive modality of pain control in surgery. More recently, there has been a surge in interest in the utility of long-acting liposomal bupivacaine (LB) for improving postoperative pain control. In 2011, LB (Exparel, Pacira Pharmaceuticals, San Diego, CA) was approved by the US Food and Drug Administration (FDA) for use as a local anesthetic at doses up to 266 mg for surgical site infiltration. LB is composed of a phospholipid bilayer that encapsulates bupivacaine, which allows for slow release of the drug. This formulation results in extended delivery of the drug for up to 72 hours after initial administration.\textsuperscript{11} To date, while findings are mixed, there is evidence to suggest that LB may improve pain control and decrease opioid requirements when utilized as part of a multi-modal pain control regimen.\textsuperscript{12}

In the setting of spine surgery, specifically, LB has been associated with improvements in postoperative pain control, decreased total narcotic utilization, and shorter hospital stays. However, the number of investigative studies is small and mainly limited to the setting of single-level surgery.\textsuperscript{9,10,13,14} As such, the utility of this drug in the setting of adult deformity surgery has not been studied to date. Consequently, the primary objectives of this study were to determine whether LB (1) reduces postoperative narcotic utilization when compared to plain bupivacaine alone and (2) improves postoperative visual analogue scale scores (VAS) following adult deformity surgery. Secondary objectives were to assess the effect of LB on hospital length of stay and perioperative complication rates. We hypothesized that LB use would result in improvements in postoperative pain, ultimately decreasing narcotic utilization and hospital lengths of stay in patients undergoing ASD correction.

**Materials and Methods**

This was a retrospective cohort study with a historical comparative group conducted within a single surgeon’s clinical practice. All adult patients >18 years of age undergoing either elective primary or revision long instrumented fusion (≥7 levels) between 2012 and 2017 were included in the study. Exclusion criteria included tumor, infection, and trauma cases. All patients underwent spinal deformity correction at a single hospital.

Patient characteristics were obtained from the practice database. These included demographic information (age and sex), surgical diagnoses, surgical procedure, as well as baseline comorbidities and surgical history.

Outcome measures included postoperative VAS scores for back pain collected every 4 hours averaged over each postoperative day (POD), inpatient opioid use (converted to oral morphine-equivalents), and total hospital lengths of stay. Additionally, all perioperative complications were recorded. Finally, Oswestry Disability Index (ODI) scores were obtained at the initial preoperative visit and at the 6-week postoperative visit.

**Intervention Versus Comparative Cohort**

All patients underwent deformity correction under general anesthesia. Prior to incision, both groups received perinec- sional 30 mL of 0.5\% bupivacaine with epinephrine (5 mg/mL). At the conclusion of the case, the Exparel cohort received 20 mL of LB (266 mg) diluted to 120 cc with NS (normal saline) into both the paraspinal musculature and subcutaneous tissue, bilaterally, along their entire lengths utilizing an 18-gauge spinal needle. The comparative cohort received 30 mL of 0.5\% bupivacaine utilizing a similar distribution technique. All patients were then admitted to the hospital and began physical therapy for postoperative mobilization on day 1 following surgery.

The standard postoperative pain regimen included initial patient-controlled anesthesia with 0.2 mg dilaudid Q8 min with an additional Q1 hour nurse directed bolus of 0.4 mg as needed for breakthrough pain. Additional medications included 650 mg PO (per os) acetaminophen Q4 hour, PO oxycodone 5 mg 1 to 2 tablets Q4 hour, PO Flexeril 5 mg Q8 hour, or PO valium 5 mg Q8 hour. Nonnarcotic naïve individuals additionally were prescribed oxycotin 10 mg PO BID.

**Statistical Analysis**

Unadjusted group comparisons were performed with the use of χ\textsuperscript{2} and student t tests. Shapiro-Wilks was used to test for normality. A χ\textsuperscript{2} test was used for categorical variables, and an independent Student’s t test was used to assess continuous variables. Generalized linear mixed models were used to compare the temporal trend of postoperative outcomes. A P < .05 was set as our measure of statistical significance.

**Source of Funding**

There was no external source of funding.

**Results**

**Patient Characteristics and Surgical Factors**

A total of 159 patients met inclusion criteria. There were 90 patients who received LB (group L) and 69 patients in the historical cohort who received bupivacaine alone (group C).
Mean age was no different between the 2 cohorts. There was no difference in comorbidity profile and surgical diagnoses between the 2 cohorts. All descriptive characteristics of both cohorts are shown in Table 1.

**Postoperative Opioid Utilization**

Group L received 259 mg of total morphine-equivalents versus 316 mg in Group C over the course of their hospitalization. Group L appeared to transition off intravenous (IV) narcotics significantly faster, with 52.6% less IV use by postoperative day 3 compared with the control arm (12.0 vs 25.4 mg, \(P = .03\)). Otherwise, no statistically significant differences were noted at any time point in opioid consumption between groups (IV, PO, and total consumption). Trends in narcotic utilization (IV, PO, and total consumption) are demonstrated in Figures 1 through 3. Finally, linear regression analyses revealed no difference between any of the trends in narcotic consumption.

**Postoperative Pain Scores**

On POD1 there was a mild difference in postoperative pain experienced between group L when compared with group C (4.8 compared to 5.7; \(P = .02\)). Otherwise, no further differences in pain scores were appreciated between the 2 cohorts following surgery (Figure 4). Linear regression analysis revealed no difference between the trends in pain scores between the 2 cohorts.

**Total Hospital Length of Stay and Perioperative Complications**

No meaningful difference in lengths of stay were observed between the 2 cohorts (L: 4.7 vs C: 4.8). There were also no differences in postoperative complication rates overall (Table 2). Specifically, there was ileus (L: 7 [7.8%] vs C: 3 [4.3%]; \(P = .216\)) and superficial wound infection (L: 1 [1.1%] vs C: 0; \(P = .189\)).

**Patient-Reported Outcome Measures**

No differences between preoperative and postoperative ODI scores were observed between the 2 cohorts.

**Discussion**

Traditionally, opioid medications have been the cornerstone of postoperative pain management in surgery. However, as narcotic overuse has become more prevalent, a substantial increase in the rate of opioid dependency, drug-related deaths, and surge in health care resource utilization\(^{15-18}\) has ensued.

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Inpatient intravenous (IV) opioid consumption (expressed in morphine-equivalents).

---

**Table 1.** Patient Baseline Characteristics and Surgical Factors.

| Parameter                          | Group L (N = 90) | Group C (N = 69) | P Value |
|------------------------------------|------------------|------------------|---------|
| Female                             | 70% (63)         | 71% (49)         | 0.04    |
| Mean age                           | 54.5 SD 20.8     | 54.0 SD 19.6     | 0.89    |
| Revision surgery                   | 41.1% (37)       | 44.9% (31)       | 0.34    |
| VAS-Back pain                      | 5.6              | 6.5              | 0.01    |
| ODI                                | 41%              | 44%              | 0.33    |
| CCI                                | 1.43             | 1.14             | 0.88    |
| Opioid naive                       | 56% (51)         | 46% (32)         | 0.25    |
| Surgical Diagnosis                 |                  |                  |         |
| Adult scoliosis                    | 13%              | 3%               |         |
| Degenerative scoliosis             | 31%              | 36%              |         |
| Kyphosis                           | 21%              | 26%              |         |
| Kyphoscoliosis                     | 34%              | 35%              |         |
| Osteotomy (3-column)               | 12.2% (11)       | 7.2% (5)         | 0.151   |
| Bilateral iliac screw              | 41.1% (37)       | 17.4% (12)       | 0.001   |
| Number of levels fused             | 10.1             | 9.3              | 0.072   |

Abbreviations: Group L, patients who received liposomal bupivacaine; Group C, patients who received plain bupivacaine; VAS, visual analogue scale; ODI, Oswestry Disability Index; CCI, Charlson Comorbidity Index.
Consequently, new government regulations have emerged that place greater restrictions on the ability of physicians to prescribe narcotics with some laws even penalizing surgeons for excessive utilization.\(^{19}\) Perhaps most concerning is the considerable side effect profile of opioid medications, which includes respiratory depression, gastrointestinal dysmotility, confusion, and even death.\(^{20}\) Furthermore, excessive narcotic utilization in the postoperative period has been linked to paradoxically poorer long-term pain control.\(^{21,22}\)

Relatedly, a direct link between adequate pain management and improved perioperative outcomes has been established. Shorter hospitalizations, quicker postoperative mobilization, and a lower rate of perioperative complications are all cited benefits of satisfactory postoperative pain control.\(^{9,10}\) Appropriate management of postoperative pain may even decrease rates of chronic pain syndromes.\(^{14,23}\) Furthermore, since 2002, the Agency for Health Care Research and Quality developed the HCAHPS survey, a standardized national survey that allows for direct patient assessment of their perceived quality of hospital care with adequate pain management being one of the quality metrics observed. Inevitably, in light of these aforementioned issues, there has been a surge in interest in the development of the optimal multimodal postoperative pain regimen in all surgical settings.\(^{24}\)

In spine surgery, early evidence has demonstrated that multimodal pain regimens can result in improved postoperative pain control, decreased narcotic utilization, improved overall outcomes, and patient satisfaction following spinal

**Figure 2.** Inpatient (PO) opioid consumption (expressed in morphine-equivalents).

**Figure 3.** Inpatient total opioid consumption (expressed in morphine-equivalents).
surgery.\(^{20,25}\) While the optimal pain management protocol remains to be determined, the use of adjunctive local infiltrative anesthetics has shown some utility.\(^{20,25-27}\) Most recently, as there has been literature to support the use of LB as part of a successful multifaceted pain control protocol in many surgical settings,\(^{28-31}\) investigations have been undertaken to determine whether or not this same benefit can be translated into the setting of spine surgery.

While limited in nature, these aforementioned studies have demonstrated that in the setting of single-level spinal surgery, LB may be of benefit. Kim et al found that in patients undergoing single-level transforaminal lumbar interbody fusion, the use of LB resulted in decreased postoperative pain and narcotic consumption in the first 24 hours following surgery. They suggested that this may have ultimately contributed to shorter hospital lengths of stay.\(^{13}\) Similarly, in a recent retrospective case-control study by Tomov et al, adjunctive use of LB was associated with decreased IV opioid consumption in patients undergoing single-level transforaminal lumbar interbody fusion when compared with standard bupivacaine alone.\(^{10}\) Finally, in patients undergoing open single-level microdiscectomies, LB was found to significantly decrease the amount of time that patients required IV narcotics postoperatively.\(^{9}\) Brown et al performed a safety study in the setting of 1- to 2-level lumbar surgeries and found LB to be safe, but did not report on pain and opioid consumption.\(^{32}\) Ultimately, as these studies were conducted in surgical settings associated with relatively low morbidity, the applicability of these findings to large spinal deformity correction may be limited.

Only 2 studies to date, that we are aware of, have evaluated the efficacy of LB in spinal deformity. Both retrospective studies investigated the use of LB as an adjunct to existing multimodal pain regimens in patients undergoing pediatric spinal deformity correction.\(^{33,34}\) Cloyd et al found no difference in postoperative opioid use or postoperative pain scores with use of LB in their study. On the other hand, Chughtai et al found that the addition of perincisional LB at closure of surgery improved these aforementioned metrics. However, there are significant limitations to the latter study. First, they compared their results to a historical cohort of patients who had not received any apparent local anesthetic postoperatively. Furthermore, the results of this study should be interpreted with careful optimism as the authors reported a direct conflict of interest with the drug manufacturer. A recent review of all level-1 studies in orthopedic surgery investigating the efficacy of LB found that studies reporting a direct conflict of interest with the manufacturer were more likely to report more optimistic outcomes. In fact, of the 9/27 studies that reported superiority of outcomes with use of LB, 8 reported a direct conflict of interest with the manufacturer.\(^{35}\)

In our study, when compared to plain bupivacaine alone, while LB appeared to result in an improvement in pain scores on POD1, these differences were small, and likely clinically irrelevant. Otherwise, no further differences in pain scores were detected between the 2 groups. Interestingly, patients receiving LB did appear to transition more quickly off of IV narcotics with a 52% reduction in narcotic consumption observed in group L on POD3. However, this difference did not appear to result in any differences in overall narcotic consumption or hospital length of stay between the 2 cohorts.

There are several notable limitations in this study. First, the retrospective, nonrandomized study design and the consequent lack of appropriate blinding in the study limit the strength of our findings. Additionally, the use of a historical cohort potentially introduces selection bias. However, no statistically or clinically significant differences in patient characteristics were found when comparing the 2 groups. Also the relatively short study interval may have limited our ability to detect any meaningful changes in the clinical management of these patients. Interestingly, a higher proportion of patients in Group L underwent bilateral iliac screw fixation, which may have confounded results. Additionally, no cost analysis was performed. On average, the difference in cost between LB and plain bupivacaine is approximately $300.\(^{36,37}\) While we would argue that in the setting of large deformity surgery this is a relatively trivial cost

---

**Figure 4. Inpatient pain scores.**

**Table 2. Complications by Group.**

| Parameter                        | Group L (N = 90) | Group C (N = 69) | P Value |
|----------------------------------|-----------------|-----------------|---------|
| Ileus                            | 7 (7.8%)        | 3 (4.3%)        | .216    |
| Wound dehiscence                 | 2 (2.2%)        | 0 (0.0%)        | .106    |
| Surgical site infection          | 1 (1.1%)        | 0 (0.0%)        | .189    |
| Respiratory failure              | 2 (2.2%)        | 1 (1.4%)        | .379    |
| Urinary retention                | 1 (1.1%)        | 1 (1.4%)        | .379    |
| Urinary tract infection          | 1 (1.1%)        | 1 (1.4%)        | .379    |
| Sepsis                           | 0 (0.0%)        | 1 (1.4%)        | .207    |
| Renal failure                    | 0 (0.0%)        | 0 (0.0%)        | 1.000   |
| Neurologic injury                | 3 (3.3%)        | 1 (1.4%)        | .249    |
| Cerebrovascular event            | 0 (0.0%)        | 1 (1.4%)        | .207    |

Abbreviations: Group L, patients who received liposomal bupivacaine; Group C, patients who received plain bupivacaine.
for the added benefit of decreasing overall narcotic consumption, we found no such difference in our study. Finally, the efficacy of the recommended dosage of LB, while perhaps useful in the setting of single-level surgery, may be significantly limited in large deformity surgeries given the dilutional effect of using the same dose in a much larger wound. Nonetheless, these limitations are accepted in exchange for the novelty of this study as this is the first study to evaluate the use of infiltrative LB as an adjunct modality of pain control in ASD surgery as far as we are aware.

Conclusion

The use of LB in ASD surgery does not appear to provide clinically important improvements in postoperative pain at the manufacturer recommended dosage. Furthermore, while patients receiving LB may transition more quickly off of IV narcotics, this does not appear to translate into an overall decrease in narcotic consumption, hasten return of bowel function, or decrease hospital lengths of stay. Future prospective randomized control trials are warranted. The use of varying dosages of LB may also help further clarify the true efficacy of LB in the setting of spinal deformity surgery.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Andrew S. Chung, DO @ https://orcid.org/0000-0003-3942-9595

References

1. Ailon T, Scheer JK, Lafage V, et al; International Spine Study Group. Adult spinal deformity surgeons are unable to accurately predict postoperative spinal alignment using clinical judgment alone. Spine Deform. 2016;4:323-329. doi:10.1016/j.spinepd.2016.02.003
2. Liu S, Diebo BG, Henry JK, et al. The benefit of nonoperative treatment for adult spinal deformity: identifying predictors for reaching a minimal clinically important difference. Spine J. 2016;16:210-218. doi:10.1016/j.spinee.2015.10.043
3. Riley MS, Bridwell KH, Lenke LG, Dalton J, Kelly MP. Health-related quality of life outcomes in complex adult spinal deformity surgery. J Neurosurg Spine. 2018;28:194-200. doi:10.3171/2017.6.SPINE17357
4. Bess S, Line B, Fu KM, et al. The health impact of symptomatic adult spinal deformity: comparison of deformity types to United States population norms and chronic diseases. Spine (Phila Pa 1976). 2016;41:224-233. doi:10.1097/BRS.0000000000001202
5. Transfeldt EE, Topp R, Mehbod AA, Winter RB. Surgical outcomes of decompression, decompression with limited fusion, and decompression with full curve fusion for degenerative scoliosis with radiculopathy. Spine (Phila Pa 1976). 2010;35:1872-1875. doi:10.1097/BRS.0b013e3181ee63a2
6. American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012;116:248-273. doi:10.1097/ALN.0b013e31823c1030
7. Wells N, Pasero C, Mccaffery M. Chapter 17: improving the quality of care through pain assessment and management. In: Hughes RG, ed. Patient Safety and Quality: An Evidence-Based Handbook for Nurses. Vol 1. Agency for Healthcare Research and Quality; 2008.
8. Wu CL, Naqibuddin M, Rowlingson AJ, Lietman SA, Jemyn RM, Fleisher LA. The effect of pain on health-related quality of life in the immediate postoperative period. Anesth Analg. 2003;97:1078-1085.
9. Puffer RC, Tou K, Winkel RE, Bydon M, Currier B, Freedman BA. Liposomal bupivacaine incisional injection in single-level lumbar spine surgery. Spine J. 2016;16:1305-1308. doi:10.1016/j.spinee.2016.06.013
10. Tomov M, Tou K, Winkel R, et al. Does subcutaneous infiltration of liposomal bupivacaine following single-level transforminal lumbar interbody fusion surgery improve immediate postoperative pain control? Asian Spine J. 2018;12:85-93. doi:10.4184/asj.2018.12.1.85
11. Pacira BioSciences Inc. Accessed June 2, 2018. www.exparel.com
12. Malik O, Kaye AD, Kaye A, Belani K, Urman RD. Emerging roles of liposomal bupivacaine in anesthesia practice. J Anaesthesiol Clin Pharmacol. 2017;33:151-156. doi:10.4103/joacp.JOACP_375_15
13. Kim J, Burke SM, Kryzanski JT, et al. The role of liposomal bupivacaine in reduction of postoperative pain after transforminal lumbar interbody fusion: a clinical study. World Neurosurg. 2016;91:460-467. doi:10.1016/j.wneu.2016.04.058
14. Grieff AN, Ghobrial GM, Jallo J. Use of liposomal bupivacaine in the postoperative management of posterior spinal decompression. J Neurosurg Spine. 2016;25:88-93. doi:10.3171/2015.11.SPINE15957
15. Shah A, Hayes CJ, Martin BC. Factors influencing long-term opioid use among opioid naive patients: an examination of initial prescription characteristics and pain etiologies. J Pain. 2017;18:1374-1383. doi:10.1016/j.jpain.2017.06.010
16. Sayal P, Bateman BT, Menendez M, Eikermann M, Ladha KS. Opioid use disorders and the risk of postoperative pulmonary complications. Anesth Analg. 2018;127:767-774. doi:10.1213/ANE.0000000000003307
17. Meyer R, Patel AM, Rattana SK, Quock TP, Mody SH. Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Popul Health Manag. 2014;17:372-387. doi:10.1089/pop.2013.0098
18. Scarpati LM, Kirson NY, Jia ZB, Wen J, Howard J. Opioid abuse: a detailed examination of cost drivers over a 24-month follow-up period. J Manag Care Spec Pharm. 2017;23:1110-1115. doi:10.18553/jmcp.2017.17019
19. Soelberg CD, Brown RE, Du Vivier D, Meyer JE, Ramachandran BK. The US opioid crisis: current federal and state legal issues. *Anesth Analg*. 2017;125:1675-1681. doi:10.1213/ANE.0000000000002403

20. Devin CJ, McGirt MJ. Best evidence in multimodal pain management in spine surgery and means of assessing postoperative pain and functional outcomes. *J Clin Neurosci*. 2015;22:930-938. doi:10.1016/j.jocn.2015.01.003

21. Bot AGJ, Bekkers S, Arnstein PM, Smith RM, Ring D. Opioid use after fracture surgery correlates with pain intensity and satisfaction with pain relief. *Clin Orthop Relat Res*. 2014;472:2542-2549. doi:10.1007/s11999-014-3660-4

22. Nota SPFT, Spit SA, Voskuyl T, Bot AGJ, Hageman MGJS, Ring D. Opioid use, satisfaction, and pain intensity after orthopedic surgery. *Psychosomatics*. 2015;56:479-485. doi:10.1016/j.psym.2014.09.003

23. Ong CKS, Lirk P, Seymour RA, Jenkins BJ. The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. *Anesth Analg*. 2005;100:757-773. doi:10.1213/01.ANE.0000144428.98767.0E

24. Asher AL, McCormick PC, Selden NR, Ghogawala Z, McGirt MJ. The National Neurosurgery Quality and Outcomes Database and NeuroPoint Alliance: rationale, development, and implementation. *Neurosurg Focus*. 2013;34:E2. doi:10.3171/2012.10.FOCUS12311

25. Kurdi MF, Kreitz T, Schroeder G, Vaccaro AR. The role of multimodal analgesia in spine surgery. *J Am Acad Orthop Surg*. 2017;25:260-268. doi:10.5435/JAAOS-D-16-00049

26. Reynolds RAK, Legakis JE, Tweedie J, et al. Postoperative pain management after spinal fusion surgery: an analysis of the efficacy of continuous infusion of local anesthetics. *Global Spine J*. 2013;3:7-14. doi:10.1016/j.glosp Jah.2013.11.18282137119

27. Elder JB, Hoh DJ, Liu CY, Wang MY. Postoperative continuous paravertebral anesthetic infusion for pain control in posterior cervical spine surgery: a case-control study. *Neurosurgery*. 2010;66(3 suppl operative):99-107. doi:10.1227/01.NEU.0000349208.87863.B3

28. Mulligan RP, Morash JG, DeOrio JK, Parekh SG. Liposomal bupivacaine versus continuous popliteal sciatic nerve block in total ankle arthroplasty. *Foot Ankle Int*. 2017;38:1222-1228. doi:10.1177/1071100717722366

29. Alter TH, Liss FE, Ilyas AM. A prospective randomized study comparing bupivacaine hydrochloride versus bupivacaine liposome for pain management after distal radius fracture repair surgery. *J Hand Surg Am*. 2017;42:1003-1008. doi:10.1016/j.jhsa.2017.08.022

30. Mont MA, Beaver WB, Dysart SH, Barrington JW, Del Gaizo DJ. Local infiltration analgesia with liposomal bupivacaine improves pain scores and reduces opioid use after total knee arthroplasty: results of a randomized controlled trial. *J Arthroplasty*. 2018;33:90-96. doi:10.1016/j.arth.2017.07.024

31. Gorfin SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. *Dis Colon Rectum*. 2011;54:1552-1559. doi:10.1097/DCR.0b013e3182323d4c1

32. Brown L, Weir T, Koenig S, et al. Can liposomal bupivacaine be safely utilized in elective spine surgery? *Global Spine J*. 2019;9(2):133-137. doi:10.1177/2192568218755684

33. Chughtai M, Sultan AA, Hudson B, et al. Liposomal bupivacaine is both safe and effective in controlling postoperative pain after spinal surgery in children: a controlled cohort study [published online April 21, 2020]. *Clin Spine Surg*. doi:10.1097/BSD.0000000000000996

34. Cloyd C, Moffett BS, Bernhardt MB, Monico EM, Patel N, Hanson D. Efficacy of liposomal bupivacaine in pediatric patients undergoing spine surgery. *Paediatr Anaesth*. 2018;28:982-986. doi:10.1111/pan.13482

35. Abildgaard JT, Chung AS, Tokish JM, Hattrup SJ. Clinical efficacy of liposomal bupivacaine: a systematic review of prospective, randomized controlled trials in orthopaedic surgery. *JBJS Rev*. 2019;7:8. doi:10.2106/JBJS.RVW.18.00192

36. Barrington JW, Emerson RH, Lovaldi ST, Lombardi AV, Berend KR. No difference in early analgesia between liposomal bupivacaine injection and intrathecal morphine after TKA. *Clin Orthop Relat Res*. 2017;475:94-105. doi:10.1007/s11999-016-4931-z

37. Schroer WC, Diesfeld PG, LeMarr AR, Morton DJ, Reedy ME. Does extended-release liposomal bupivacaine better control pain than bupivacaine after total knee arthroplasty (TKA)? A prospective, randomized clinical trial. *J Arthroplasty*. 2015;30(9 suppl):64-67. doi:10.1016/j.arth.2015.01.059